The Company plans to submit a Phase 2 trial protocol for SER-155 in allo-HSCT to the FDA in the coming weeks and is actively seeking partners to support continued clinical development. Presentation Details Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or th ...